Pipeline
A robust pipeline to treat the most resistant cancers and neurological diseases
Hard to treat cancers and neurodegenerative diseases demand a diverse arsenal of novel therapeutic approaches.
From monoclonal and bispecific antibodies, to antibody drug conjugates, discover what we have in development.
Fully-owned clinical assets
PD-1/VEGF
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
AI-081
Solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
SIGLEC10
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
ONC-841
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
ONC-841
Alzheimer’s disease
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Fully-owned pre-clinical assets
CD24
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
ONC-783
Hematologic malignancies
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
ONC-784
Solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Late-Stage Clinical Asset in Partnership with BioNTech
CTLA-4
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
Gotistobart
(ONC-392)
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Gotistobart
(ONC-392)*
Advanced solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Gotistobart
(ONC-392)
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
*In partnership with
Clinical trials recruiting now
We are currently recruiting patients for 4 clinical trials in a range of indications.
If you or someone you care about is battling cancer, we welcome you to learn more and get in touch.
BIPAVE-001
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
Indications: metastatic disease or locally advanced solid tumors
PRESERVE-004
A Phase 2 study that compares two doses of gotistobart in combination with a fixed dose of pembrolizumab
Indications: Platinum-resistant ovarian cancer
PRESERVE-001
A Phase 1 open-label study of gotistobart as a monotherapy and in combination with Pembrolizumab
Indications: Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cance, Ovarian Cance, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction adenocarcinoma, Cervical Cancer, AAdenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
PRESERVE-006
A Phase 2 study examining the safety and efficacy of gotistobart in combination with lutetium Lu 177 vipivotide tetraxetan
Indications: Metastatic Castration-resistant Prostate Cancer
PRESERVE-003
A Phase 3 study of gotistobart versus docetaxel
Indications: Non-Small Cell Lung Cancers that Progressed on PD-1/PD-l1 Inhibitors
ONC-841-002
Safety, Pharmacokinetics (PK) and Efficacy of ONC-841 in Advanced Solid Tumors NCT06352359
Indications: Advanced or metastatic cancers
Clinical trials recruiting soon
For further inquiries about our clinical trials, don’t hesitate to reach out.